The Journal of Steroid Biochemistry and Molecular Biology
Mechanisms of the actions of aromatase inhibitors 4-hydroxyandrostenedione, fadrozole, and aminoglutethimide on aromatase in JEG-3 cell culture
References (32)
- et al.
Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3,17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivo
Steroids
(1981) - et al.
The involvement of human placental microsomal cytochrome P450 in aromatization
J. Biol. Chem.
(1974) - et al.
Estrogen synthetase in choriocarcinoma cell culture
Stimulation by dibutyryl cyclic adenosine monophosphate and theophylline
Steroids
(1978) - et al.
Time-dependent inhibition of aromatase in trophoblastic tumor cells in tissue culture
J. Steroid. Biochem.
(1984) - et al.
Synthesis of deuterium- and tritium-labeled 4-hydroxyandrostene-3,17-dione, an aromatase inhibitor, and its metabolism in vitro and in vivo in the rat
Biochem. Pharmacol.
(1982) - et al.
Protein measurement with the Folin phenol reagent
J. Biol. Chem.
(1951) - et al.
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
Anal. Biochem.
(1987) - et al.
Aromatase in the human choriocarcinoma JEG-3: inhibition by R76 713 in cultured cells and in tumors grown in nude mice
J. Steroid. Biochem. Molec. Bio.
(1991) - et al.
Growth suppression of MCF-7 human breast cancer cells by aromatase inhibitors: a new system for aromatase inhibitor screening
J. Steroid Biochem. Molec. Biol.
(1993) - et al.
Studies on the mechanism of estrogen biosynthesis. VII. The development of inhibitors of the enzyme system in human placenta
Endocrinol.
(1973)
Aromatase Inhibitors and Breast Cancer
Seminars in Oncology
The effect of an aromatase inhibitor, 4-hydroxy-4-androstene-3,17-dione, on estrogen-dependent processes in reproduction and breast cancer
Endocrinol.
In vitro and in vivo studies demonstrating potent and selective estrogen inhibition with the nonsteroidal aromatase inhibitor FadrozoleA
Steroids
Amino glutethimide as an inhibitor of adrenal steroidogenesis mechanism of action and therapeutic trial
J. Chin. Endocrinol. Metab.
Endocrine changes associated with relapse in advanced breast cancer patients on aminoglutethimide therapy
J. Clin. Endocr. Metab.
Characterization of steroid production in cultured human choriocarcinoma cells
J. Clin. Endocrinol. Metab.
Cited by (46)
Prenatal aromatase inhibition alters postnatal immunity in domestic chickens (Gallus gallus)
2020, General and Comparative EndocrinologyTributyltin and triphenyltin induce 11β-hydroxysteroid dehydrogenase 2 expression and activity through activation of retinoid X receptor α
2020, Toxicology LettersCitation Excerpt :The efficacy of 5 μg/mL CHX in blocking protein synthesis in JEG-3 cells was tested by assessment of 50 nM Bex-induced 11β-HSD2 protein levels and was found to totally abolish the de novo 11β-HSD2 protein synthesis (data not shown). Additionally, this concentration of CHX was shown earlier to significantly inhibit protein synthesis in JEG-3 cells and was utilized to study the effect of angiotensin II on 11β-HSD2 expression under conditions of translational inhibition (Lanz et al., 2003; Yue and Brodie, 1997). To study whether upregulation of 11β-HSD2 mRNA results from enhanced gene transcription, cells were simultaneously incubated with 50 nM organotins or Bex and the transcriptional inhibitor Act D. Inhibition of transcription significantly prevented the increase of 11β-HSD2 mRNA upon exposure to TBT, TPT and Bex compared to control (Fig. 5B).
The steroid metabolite 16(β)-OH-androstenedione generated by CYP21A2 serves as a substrate for CYP19A1
2017, Journal of Steroid Biochemistry and Molecular BiologyCitation Excerpt :In contrast, additional hydroxylations of A4 or T have been shown to dramatically affect binding properties of CYP19A1. For example, it was already shown that 4-hydroxy-androstenedione, which is used for the treatment of breast cancer, irreversibly binds to CYP19A1 [36,37]. In order to investigate whether 16bOHA4 is metabolized by CYP19A1 we performed a reconstituted in vitro assay, consisting of recombinantly expressed and purified human CYP19A1 and human CPR.
Evaluation of a bioluminescent mouse model expressing aromatase PII-promoter-controlled luciferase as a tool for the study of endocrine disrupting chemicals
2010, Toxicology and Applied PharmacologyCitation Excerpt :Primary cell cultures, although more relevant for mechanistic studies and environmental/species relevance than cancer cell lines, have as disadvantage that they are difficult to obtain, maintain and standardize, and loss of gene expression may occur over time. In vitro studies in human placental microsomes or cell lines have shown that aromatase may be inhibited or induced by various environmental chemicals, medications or naturally occurring dietary compounds (Mason et al., 1987; Ibrahim and Abul-Hajj, 1990; Campbell and Kurzer, 1993; Yue and Brodie, 1997; Drenth et al., 1998; Le Bail et al., 1998; Vinggaard et al., 2000; Saarinen et al., 2001; Andersen et al., 2002; Sanderson et al., 2002, 2004; Fernandez-Canton et al., 2003; Ohno et al., 2004; Heneweer et al., 2005; Letcher et al., 2005; Sanderson, 2006; He et al., 2008). For example, various dietary (iso)flavonoids induce (genistein, quercetin) or inhibit (chrysin, apigenin) human aromatase activity (Sanderson et al., 2004) and anti-breast cancer medications, such as fadrozole, letrozole and anastrozole (Miller and Dixon, 2000), as well as various pesticides (Vinggaard et al., 2000; Sanderson et al., 2002), are highly potent inhibitors of its catalytic activity.
Cell density is a critical determinant of aromatase expression in adipose stromal cells
2010, Journal of Steroid Biochemistry and Molecular BiologyIn situ hybridization to detect spatial gene expression in medaka
2009, Ecotoxicology and Environmental Safety